Xilio appoints Kevin Brennan as SVP, Finance and Accounting, principal financial officer

Xilio Therapeutics, Inc.

Kevin Brennan joined Xilio on March 30, 2023 as SVP, Finance and Accounting and principal financial/accounting officer.
Brennan receives annual base salary of $370,000, target bonus of 35% of base salary.
Granted stock option to purchase 55,000 shares; vests 25% on first anniversary, 75% monthly over 3 years.
Board adopted amended and restated bylaws updating stockholder meeting procedures and universal proxy rules.
Bylaw amendments also include enhanced advance notice disclosure requirements and technical changes.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kevin Brennan

Senior Vice President, Finance and Accounting

XLO · Xilio Therapeutics, Inc.

Effective: 2023-03-30
Filed: April 3, 2023, 7:59 PM ET

On March 30, 2023, Kevin Brennan joined Xilio Therapeutics, Inc. (the “Company”) as Senior Vice President, Finance and Accounting, and the board of directors (the “Board”) of the Company appointed Mr. Brennan to serve as the Company’s principal financial officer and principal accounting officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin Brennan was appointed as Senior Vice President, Finance and Accounting at Xilio Therapeutics, Inc..

Action: appointed
Role: Senior Vice President, Finance and Accounting

Exact text from the filing

On March 30, 2023, Kevin Brennan joined Xilio Therapeutics, Inc. (the “Company”) as Senior Vice President, Finance and Accounting, and the board of directors (the “Board”) of the Company appointed Mr. Brennan to serve as the Company’s principal financial officer and principal accounting officer.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Xilio Therapeutics, Inc.: Adopted Second Amended and Restated Bylaws to amend stockholder meeting procedures, voting list requirements, adjournment procedures, advance notice requirements, proxy card color, eliminate director compensation provision, and make technical and conforming changes (effective 2023-03-28).

Change: bylaw amendment
Effective: 2023-03-28

Exact text from the filing

On March 28, 2023, the Board adopted amended and restated bylaws of the Company (as amended and restated, the “Second Amended and Restated Bylaws”), effective immediately

View on SEC.gov

83 governance changes filed in the last 30 days. Browse all governance changes →

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-005393

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.